SCHEMBL25926503

SCHEMBL25926503

CNN1C(=O)CSc2ccc(C(=O)Nc3ccc(CN4CCCCCC4)cc3)cc21

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 5/20 0.54
▸ LMNA P02545 2/20 0.54
▸ HTT P42858 2/20 0.54
▸ GAA P10253 2/20 0.54
▸ KMT2A Q03164 1/20 0.54
▸ TNF P01375 1/20 0.53
▸ HPGD P15428 1/20 0.52
▸ MAPT P10636 6/20 0.52
▸ SMN1; SMN2 Q16637 5/20 0.52
▸ TP53 P04637 1/20 0.52
▸ KDM4E B2RXH2 4/20 0.48
▸ ALDH1A1 P00352 3/20 0.48
▸ CYP1A2 P05177 1/20 0.48
▸ CYP2D6 P10635 1/20 0.48
▸ CYP2C9 P11712 1/20 0.48
▸ ALOX15 P16050 1/20 0.48
▸ NPC1 O15118 5/20 0.47
▸ MAPK1 P28482 2/20 0.47
▸ PPARG P37231 1/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24124898 0.89 MAPT (0.57) RAB9ALMNAHTTGAAKMT2A
SCHEMBL24124186 0.89 MAPT (0.57) RAB9ALMNAHTTGAAKMT2A
SCHEMBL24124187 0.75 TRPV1 (0.67) RAB9ALMNAHTTGAAKMT2A
SCHEMBL24125225 0.74 ALDH1A1 (0.51) RAB9AHTTKMT2ATNFMAPT
SCHEMBL24124782 0.74 MAPT (0.55) LMNAMAPTSMN1; SMN2TP53ALDH1A1
SCHEMBL24124676 0.73 MAPT (0.55) RAB9ALMNAHTTKMT2AMAPT
SCHEMBL24125006 0.73 ALDH1A1 (0.59) RAB9AKMT2AMAPTSMN1; SMN2TP53
SCHEMBL13683732 0.72 TNF (0.75) RAB9ALMNAHTTGAAKMT2A
SCHEMBL13211852 0.72 TNF (0.75) RAB9ALMNAHTTGAAKMT2A
SCHEMBL25927899 0.72 CTDSP1 (0.55) LMNAGAAKMT2AMAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-08-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA BCL6, SOX18, BCL3 RAB9A 1163/4885LMNA 4265/4885HTT 4222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback